Understanding cisplatin resistance using cellular models

IUBMB Life

Volumn 59, Issue 11, 2007, Pages 696-699

  Stordal, Britta ^a   Davey, Mary ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Cell models; Chemotherapy; Cisplatin; Glutathione; Leukaemia; P21; Paclitaxel; Platinum; Resistance; SCLC

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE; P21 ACTIVATED KINASE; PACLITAXEL;

CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL LINE; CELL TYPE; CROSS RESISTANCE; DNA DAMAGE; DRUG SENSITIZATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; RADIATION; REVIEW; TUMOR;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 35649024810     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540701636287     Document Type: Review

References (19)

1. Rabik, C. A., and Dolan, M. E. (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Rev. 33, 9-23.
2. Kartalou, M., and Essigmann, J. M. (2001) Mechanisms of resistance to cisplatin. Mutation Res. 478, 23-43.
3. Locke, V. L., Davey, R. A., and Davey, M. W. (2003) Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel. Anti-Cancer Drugs 14, 523-531.
4. Stordal, B. K., Davey, M. W., and Davey, R. A. (2006) Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother. Pharmacol. 58, 256-265.
5. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Institute 92, 1295-1302.
6. Henness, S., Davey, M. W., Harvie, R. M., and Davey, R. A. (2002) Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int. J. Radiat. Oncol. Biol. Physics. 54, 895-902.
7. Sasada, T., Nakamura, H., Ueda, S., Sato, N., Kitaoka, Y., Gon, Y., Takabayashi, A., Spyrou, G., Holmgren, A., and Yodoi, J. (1999) Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radical Biol. Med. 27, 504-514.
8. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biol. Med. 42, 872-881.
9. Stordal, B., Peters, G., and Davey, R. (2006) Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes Chromosomes Cancer 45, 1094-1105.
10. Siddik, Z. H., Mims, B., Lozano, G., and Thai, G. (1998) Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 58, 698-703.
11. Cummings, M., Higginbottom, K., McGurk, C. J., Wong, O. G., Koberle, B., Oliver, R. T., and Masters, J. R. (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem. Pharmacol. 72, 166-175.
12. Simon, G. R., Sharma, S., Cantor, A., Smith, P., and Bepler, G. (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127, 978-983.
13. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Investigat 94, 703-708.
14. Lord, R. V., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., Cardenal, F., Sanchez, J. M., Gumerlock, P. H., Taron, M., Sanchez, J. J., Danenberg, K. D., Danenberg, P. V., and Rosell, R. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291.
15. Smith, J. A., Gaikwad, A., Ramondetta, L. M., Wolf, J. K., and Brown, J. (2006) Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecologic Oncol. 103, 518-522.
16. Smith, J. A., Brown, J., Martin, M. C., Ramondetta, L. M., and Wolf, J. K. (2004) An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecologic Oncol. 92, 314-319.
17. Su, G. M., Davey, M. W., and Davey, R. A. (1998) Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int. J. Cancer 76, 702-708.
18. Locke, V., Davey, R., and Davey, M. (2001) Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle. Cytometry 43, 170-174.
19. Davey, R. A., Locke, V. L., Henness, S., Harvie, R. M., and Davey, M. W. (2004) Cellular models of drug- and radiation-resistant small cell lung cancer. Anticancer Res. 24, 465-471.